CSP INC /MA/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CSP INC /MA/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $58.73M | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | $55.22M | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | $64.65M | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | $54.36M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $49.21M | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | $61.79M | Dec 8, 2021 |
| FY2020 | Jun 30, 2020 | $13.78M | Dec 28, 2020 |
| FY2020 | Mar 31, 2020 | $16.88M | Dec 28, 2020 |
| FY2020 | Dec 31, 2019 | $16.86M | Dec 28, 2020 |
| FY2020 | Sep 30, 2019 | $79.06M | Dec 28, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Sep 30, 2019 | $79.06M | Dec 10, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $72.92M | Dec 27, 2018 |
| FY2018 | Sep 30, 2017 | $88.49M | Dec 27, 2018 |
| FY2017 | Sep 30, 2016 | $103.37M | Dec 22, 2017 |
| FY2016 | Sep 30, 2015 | $89.31M | Jan 13, 2017 |
| FY2015 | Sep 30, 2014 | $84.62M | Dec 24, 2015 |
| FY2014 | Sep 30, 2013 | $87.62M | Dec 23, 2014 |
| FY2013 | Sep 30, 2012 | $84.81M | Dec 24, 2013 |
| FY2012 | Sep 30, 2011 | $73.65M | Dec 20, 2012 |
| FY2011 | Sep 30, 2010 | $90.11M | Jan 13, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $18.51M | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | $18.86M | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | $21.92M | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | $18.83M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $16.15M | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | $17.17M | Dec 8, 2021 |
| FY2020 | Jun 30, 2020 | $4.22M | Dec 28, 2020 |
| FY2020 | Mar 31, 2020 | $4.48M | Dec 28, 2020 |
| FY2020 | Dec 31, 2019 | $4.03M | Dec 28, 2020 |
| FY2020 | Sep 30, 2019 | $18.03M | Dec 28, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($91.0K) | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | ($326.0K) | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | $5.20M | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | $1.89M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $699.0K | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | ($1.45M) | Dec 8, 2021 |
| FY2020 | Jun 30, 2020 | ($210.0K) | Dec 28, 2020 |
| FY2020 | Mar 31, 2020 | ($732.0K) | Dec 28, 2020 |
| FY2020 | Dec 31, 2019 | ($540.0K) | Dec 28, 2020 |
| FY2020 | Sep 30, 2019 | ($371.0K) | Dec 28, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($3.11M) | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | ($1.87M) | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | $1.87M | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | ($40.0K) | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | ($1.36M) | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | ($1.42M) | Dec 8, 2021 |
| FY2020 | Jun 30, 2020 | ($393.0K) | Dec 28, 2020 |
| FY2020 | Mar 31, 2020 | ($143.0K) | Dec 28, 2020 |
| FY2020 | Dec 31, 2019 | ($402.0K) | Dec 28, 2020 |
| FY2020 | Sep 30, 2019 | ($826.0K) | Dec 28, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.25M | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | $2.96M | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | $3.14M | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | $3.08M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $2.89M | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | $2.80M | Dec 8, 2021 |
| FY2020 | Sep 30, 2019 | $2.80M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $3.28M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $2.36M | Dec 27, 2018 |
| FY2017 | Sep 30, 2016 | $2.98M | Dec 22, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $18.37M | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | $17.77M | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | $16.91M | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | $15.78M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $14.62M | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | $15.79M | Dec 8, 2021 |
| FY2020 | Sep 30, 2019 | $16.05M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $16.72M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $15.67M | Dec 27, 2018 |
| FY2017 | Sep 30, 2016 | $18.26M | Dec 22, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.27M | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | $4.21M | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | $3.91M | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | $2.68M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $1.90M | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | $244.0K | Dec 8, 2021 |
| FY2020 | Sep 30, 2019 | ($3.33M) | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $2.88M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $2.66M | Dec 27, 2018 |
| FY2017 | Sep 30, 2016 | $5.00M | Dec 22, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $348.0K | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | $196.0K | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | $226.0K | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | $234.0K | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $98.0K | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | $230.0K | Dec 8, 2021 |
| FY2020 | Sep 30, 2019 | $832.0K | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $438.0K | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $207.0K | Dec 27, 2018 |
| FY2017 | Sep 30, 2016 | $735.0K | Dec 22, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $71.16M | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | $69.44M | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | $65.90M | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | $75.06M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $62.97M | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | $53.65M | Dec 8, 2021 |
| FY2020 | Sep 30, 2019 | $59.37M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $55.28M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $58.93M | Dec 27, 2018 |
| FY2017 | Sep 30, 2016 | $48.71M | Dec 22, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $26.61M | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | $22.17M | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | $19.76M | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | $36.10M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $28.93M | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | $24.11M | Dec 8, 2021 |
| FY2020 | Sep 30, 2019 | $28.94M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $21.47M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $37.93M | Dec 27, 2018 |
| FY2017 | Sep 30, 2016 | $31.05M | Dec 22, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $44.55M | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | $47.27M | Dec 16, 2025 |
| FY2025 | Sep 30, 2023 | $46.15M | Dec 16, 2025 |
| FY2024 | Sep 30, 2022 | $38.96M | Dec 20, 2024 |
| FY2023 | Sep 30, 2021 | $34.05M | Dec 13, 2023 |
| FY2022 | Sep 30, 2020 | $29.53M | Dec 8, 2022 |
| FY2021 | Sep 30, 2019 | $30.43M | Dec 8, 2021 |
| FY2020 | Sep 30, 2018 | $33.80M | Dec 28, 2020 |
| FY2019 | Sep 30, 2017 | $21.00M | Dec 10, 2019 |
| FY2018 | Sep 30, 2016 | $17.66M | Dec 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $27.70M | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | $29.85M | Dec 16, 2025 |
| FY2024 | Oct 1, 2023 | $15.0K | Dec 20, 2024 |
| FY2024 | Sep 30, 2023 | $31.31M | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | $26.77M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $25.19M | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | $24.49M | Dec 8, 2021 |
| FY2020 | Sep 30, 2019 | $27.25M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $29.93M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $17.41M | Dec 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $27.42M | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | $30.59M | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | $25.22M | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | $23.98M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $20.01M | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | $19.26M | Dec 8, 2021 |
| FY2020 | Sep 30, 2019 | $18.10M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $25.11M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $10.42M | Dec 27, 2018 |
| FY2017 | Sep 30, 2016 | $13.10M | Dec 22, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Dec 8, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Dec 28, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Dec 28, 2020 |
| FY2020 | Dec 31, 2019 | 0 | Dec 28, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Dec 28, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Dec 8, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Dec 28, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Dec 28, 2020 |
| FY2020 | Dec 31, 2019 | 0 | Dec 28, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Dec 28, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 9.91M | Dec 16, 2025 |
| FY2025 | Sep 30, 2024 | 9.78M | Dec 16, 2025 |
| FY2024 | Sep 30, 2023 | 9.46M | Dec 20, 2024 |
| FY2023 | Sep 30, 2022 | 4.55M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | 4.39M | Dec 8, 2022 |
| FY2021 | Sep 30, 2020 | 4.28M | Dec 8, 2021 |
| FY2020 | Sep 30, 2019 | 4.15M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | 4.02M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | 3.94M | Dec 27, 2018 |
| FY2017 | Sep 30, 2016 | 3.82M | Dec 22, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $1.92M | Dec 27, 2018 |
| FY2018 | Sep 30, 2017 | $1.72M | Dec 27, 2018 |
| FY2017 | Sep 30, 2016 | $1.67M | Dec 22, 2017 |
| FY2016 | Sep 30, 2015 | $1.62M | Jan 13, 2017 |
| FY2015 | Sep 30, 2014 | $1.55M | Dec 24, 2015 |
| FY2014 | Sep 30, 2013 | $1.38M | Dec 23, 2014 |
| FY2013 | Sep 30, 2012 | $750.0K | Dec 24, 2013 |